Emergent BioSolutions Inc. 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on March 8, 2012, by Emergent BioSolutions Inc. The report details a material definitive agreement entered into by Emergent BioDefense Operations Lansing LLC, a wholly owned subsidiary of the Company.
Key Financial Metrics and Contract Value
The filing discloses a contract with the Centers for Disease Control and Prevention (CDC) for the supply of BioThrax (Anthrax Vaccine Adsorbed). Key financial terms include:
- Maximum Contract Value: Approximately $1.25 billion, contingent on funding availability and expiration dating of delivered doses.
- Committed Funding: $225 million has been committed for the procurement of doses.
- Volume: Up to 44.75 million doses over a five-year period.
- Performance Period: September 30, 2011, through September 29, 2016.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the Company, as this report focuses solely on the material agreement.
Material Changes and Contract Status
The primary material change is the execution of the CDC Contract, effective as of September 30, 2011. Delivery of doses commenced in December 2011. While $225 million is committed, the procurement of the remaining doses is explicitly subject to the availability of future funding.
Outlook, Risks, and Contingencies
Management commentary indicates that the full realization of the $1.25 billion maximum value is not guaranteed. The primary contingency is the availability of government funding for the procurement of doses beyond the initial $225 million commitment. The contract value is also dependent on the expiration dating of the BioThrax delivered.
Key Facts for Investor Verification
- Verify the status of the $225 million committed funding and the timeline for disbursement.
- Monitor Congressional or federal budget approvals required to fund the remaining potential $1.025 billion of the contract.
- Confirm the actual volume of doses delivered since December 2011 against the 44.75 million dose cap.
- Assess the impact of the "expiration dating" clause on the final contract value.